Omnicell, Inc. (NASDAQ:OMCL) Q3 2024 Earnings Conference Call October 30, 2024 8:30 AM ET Company Participants Kathleen Neiman - Senior Vice President, Investor Relations Randall Lipps - Founder, Chairman, President & Chief Executive Officer Nchacha Etta - Executive Vice President & Chief Financial Officer Conference Call Participants Matt Hewitt - Craig-Hallum Capital Group Jessica Tassan - Piper Sandler Allen Lutz - Bank of America Stephanie Davis - Barclays Anne Samuel - JPMorgan Scott Schoenhaus - KeyBa ...

Omnicell October 30, 2024 Investor Relations Forward-Looking Statements This presentation contains "drivadelooking statements" within the meaning of feetral scurities laws. These forward-looking statements with respect to 2024 grularce, strateg opportunities, other expectations and other norshistorical information. Without limting the foregoing, statements including the world; "friters"," will", "should,"" tould," ttelleve, "forecast," guidance," "outlook," trange," "estimate," seek" predic," jtroject," and ...

Omnicell (OMCL) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.62 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 36.59%. A quarter ago, it was expected that this Omnicell Inc. Would post earnings of $0.16 per share when it actually produced earnings of $0.51, delivering a surprise of 218.75%. Over the last four quarters, the company ...

Exhibit 99.1 Contact: Kathleen Nemeth Omnicell, Inc. Senior Vice President, Investor Relations 4220 North Freeway 650-435-3318 Fort Worth, TX 76137 Kathleen.Nemeth@Omnicell.com Omnicell Announces Third Quarter 2024 Results Omnicell delivers solid third quarter financial results Total revenues of $282 million GAAP net income per diluted share of $0.19 Non-GAAP net income per diluted share of $0.56 Raises 2024 non-GAAP EBITDA and non-GAAP earnings per share guidance FORT WORTH, Texas -- October 30, 2024 -- Om ...

For Immediate ReleaseChicago, IL – October 29, 2024 – Today, Zacks Equity Research like Inspire Medical Systems (INSP) , 10x Genomics (TXG) and Omnicell, Inc. (OMCL) .Industry: Medical Info SystemsLink: https://www.zacks.com/commentary/2358816/3-medical-info-systems-stocks-to-gain-from-healthcare-digitizationStarting from healthcare resource management to efficient handling of medical records and patient data, the Medical Info Systems industry is rapidly expanding its boundaries with each passing day. Banki ...

Omnicell (OMCL) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system. Indiv ...

Here are two stocks with buy rank and strong momentum characteristics for investors to consider today, October 4: Omnicell, Inc. (OMCL) : This pharmaceutical technology company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 16.7% over the last 60 days. Omnicell's shares gained 56.3% over the last three months compared with the S&P 500's advanced of 2.3%. The company possesses a Momentum Score of B. ServisFirst Bancshares, Inc. (SFBS) : This bank holdi ...

Omnicell (OMCL) is moving closer to achieving the industry-defined vision of Autonomous Pharmacy through automation and advanced services across its cloud-based platform. The company is on track to meet its 2025 financial goals, supported by increasing tech services and long-term customer partnerships. Its strategic expansion into new regions is also encouraging. However, headwinds from competitive pressures and macroeconomic challenges could adversely affect the company's performance. In the past year, thi ...

Investors might want to bet on Omnicell (OMCL) , as earnings estimates for this company have been showing solid improvement lately. The stock has already gained solid short-term price momentum, and this trend might continue with its still improving earnings outlook. The rising trend in estimate revisions, which is a result of growing analyst optimism on the earnings prospects of this Omnicell Inc. Should get reflected in its stock price. After all, empirical research shows a strong correlation between trend ...

Omnicell, Inc. (OMCL) recently announced Central Med Automation Service, a subscription-based solution. It is designed to help health systems establish and continuously optimize centralized medication management for Consolidated Pharmacy Services Centers ("CPSCs") and similar operations. About Central Med Automation Service Intended to streamline medication dispensing from a central fulfillment area throughout the entire health system enterprise, this solution is expected to improve inventory visibility, sc ...